Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
06 03 2023
Historique:
received: 05 02 2023
revised: 02 03 2023
accepted: 03 03 2023
medline: 30 3 2023
entrez: 28 3 2023
pubmed: 29 3 2023
Statut: epublish

Résumé

Botulinum neurotoxins (BoNTs) can cause nerve paralysis syndrome in mammals and other vertebrates. BoNTs are the most toxic biotoxins known and are classified as Class A biological warfare agents. BoNTs are mainly divided into seven serotypes A-G and new neurotoxins BoNT/H and BoNT/X, which have similar functions. BoNT proteins are 150 kDa polypeptide consisting of two chains and three domains: the light chain (L, catalytic domain, 50 kDa) and the heavy chain (H, 100 kDa), which can be divided into an N-terminal membrane translocation domain (HN, 50 kDa) and a C-terminal receptor binding domain (Hc, 50 kDa). In current study, we explored the immunoprotective efficacy of each functional molecule of BoNT/F and the biological characteristics of the light chain-heavy N-terminal domain (FL-HN). The two structure forms of FL-HN (i.e., FL-HN-SC: single chain FL-HN and FL-HN-DC: di-chain FL-HN) were developed and identified. FL-HN-SC could cleave the vesicle associated membrane protein 2 (VAMP2) substrate protein in vitro as FL-HN-DC or FL. While only FL-HN-DC had neurotoxicity and could enter neuro-2a cells to cleave VAMP2. Our results showed that the FL-HN-SC had a better immune protection effect than the Hc of BoNT/F (FHc), which indicated that L-HN-SC, as an antigen, provided the strongest protective effects against BoNT/F among all the tested functional molecules. Further in-depth research on the different molecular forms of FL-HN suggested that there were some important antibody epitopes at the L-HN junction of BoNT/F. Thus, FL-HN-SC could be used as a subunit vaccine to replace the FHc subunit vaccine and/or toxoid vaccine, and to develop antibody immune molecules targeting L and HN domains rather than the FHc domain. FL-HN-DC could be used as a new functional molecule to evaluate and explore the structure and activity of toxin molecules. Further exploration of the biological activity and molecular mechanism of the functional FL-HN or BoNT/F is warranted.

Identifiants

pubmed: 36977091
pii: toxins15030200
doi: 10.3390/toxins15030200
pmc: PMC10056376
pii:
doi:

Substances chimiques

botulinum toxin type F U1R2P71O7G
Botulinum Toxins, Type A EC 3.4.24.69
Vesicle-Associated Membrane Protein 2 0
Neurotoxins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Hum Vaccin Immunother. 2020;16(1):100-108
pubmed: 31210561
Infect Immun. 2009 Jul;77(7):2795-801
pubmed: 19398544
Toxicon. 2020 Mar;176:67-76
pubmed: 32032587
Clin Vaccine Immunol. 2008 Dec;15(12):1819-23
pubmed: 18845829
Toxins (Basel). 2019 Nov 22;11(12):
pubmed: 31771110
Toxins (Basel). 2022 Feb 11;14(2):
pubmed: 35202162
Expert Rev Vaccines. 2013 May;12(5):481-92
pubmed: 23659297
Toxins (Basel). 2021 Dec 27;14(1):
pubmed: 35050996
Vaccine. 2020 Mar 23;38(14):2978-2983
pubmed: 32113807
Biochim Biophys Acta. 2016 Dec;1864(12):1678-1685
pubmed: 27596061
Vaccine. 2018 Feb 1;36(6):827-832
pubmed: 29307477
Microbiol Immunol. 2020 Jul;64(7):502-511
pubmed: 32301520
PLoS Pathog. 2022 Jan 6;18(1):e1010169
pubmed: 34990480
Toxins (Basel). 2021 Sep 10;13(9):
pubmed: 34564645
Pharmacol Rev. 2017 Apr;69(2):200-235
pubmed: 28356439
Protein Expr Purif. 2018 Jun;146:51-60
pubmed: 29407166
J Struct Biol. 2011 Apr;174(1):52-7
pubmed: 21078393
Toxins (Basel). 2018 Nov 26;10(12):
pubmed: 30486254
Biochem J. 2011 Jan 15;433(2):277-84
pubmed: 21029044
Toxins (Basel). 2021 Nov 24;13(12):
pubmed: 34941672
Annu Rev Biochem. 2019 Jun 20;88:811-837
pubmed: 30388027
Toxins (Basel). 2019 Sep 12;11(9):
pubmed: 31547338
Int J Mol Sci. 2021 Aug 09;22(16):
pubmed: 34445283
Vaccine. 2018 Apr 5;36(15):2041-2048
pubmed: 29475762
Toxins (Basel). 2019 Jan 11;11(1):
pubmed: 30641949
PLoS One. 2017 Mar 21;12(3):e0174187
pubmed: 28323873
Toxins (Basel). 2018 Jul 04;10(7):
pubmed: 29973505
Crit Rev Immunol. 2007;27(4):319-41
pubmed: 18197812
Nat Struct Mol Biol. 2009 Jul;16(7):789-94
pubmed: 19543288
Infect Immun. 2015 Apr;83(4):1465-76
pubmed: 25624352
Infect Immun. 2005 Oct;73(10):6998-7005
pubmed: 16177380
Hybridoma (Larchmt). 2012 Aug;31(4):233-9
pubmed: 22894775
Toxins (Basel). 2021 Oct 22;13(11):
pubmed: 34822535
Toxins (Basel). 2019 Jul 17;11(7):
pubmed: 31319550
Hum Vaccin Immunother. 2019;15(3):755-760
pubmed: 30433836
MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60(42):1454-5
pubmed: 22031218
Toxins (Basel). 2018 Mar 01;10(3):
pubmed: 29494481
Toxins (Basel). 2020 Aug 07;12(8):
pubmed: 32784744
Semin Neurol. 2016 Feb;36(1):10-9
pubmed: 26866491
Toxicon. 2020 Apr 30;178:20-32
pubmed: 32094099
Toxins (Basel). 2018 May 10;10(5):
pubmed: 29748471
J Infect Dis. 2016 May 15;213(10):1606-14
pubmed: 26936913
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048621
pubmed: 35435814
Toxins (Basel). 2017 Jan 18;9(1):
pubmed: 28106761
Toxins (Basel). 2021 Jan 14;13(1):
pubmed: 33466571
Protein Eng Des Sel. 2011 Mar;24(3):321-31
pubmed: 21149386
Infect Immun. 2008 Mar;76(3):1314-8
pubmed: 18070903
Toxins (Basel). 2020 Sep 24;12(10):
pubmed: 32987745
Toxins (Basel). 2017 Sep 02;9(9):
pubmed: 28869493
Toxins (Basel). 2018 Jul 02;10(7):
pubmed: 30004421
Crit Rev Immunol. 2010;30(2):167-87
pubmed: 20370628
Sci Rep. 2015 Oct 28;5:15776
pubmed: 26508475
Neurotox Res. 2021 Aug;39(4):1044-1053
pubmed: 33616873
Clin Immunol. 2010 Nov;137(2):271-80
pubmed: 20696619
Res Microbiol. 2015 May;166(4):290-302
pubmed: 25312020
Microorganisms. 2021 Oct 23;9(11):
pubmed: 34835332
Nat Rev Microbiol. 2014 Aug;12(8):535-49
pubmed: 24975322
Handb Exp Pharmacol. 2021;263:11-33
pubmed: 31792680

Auteurs

Zhiying Li (Z)

Beijing Institute of Biotechnology, Beijing 100071, China.
Pharmaceutical College, Henan University, Kaifeng 475001, China.

Bolin Li (B)

Beijing Institute of Biotechnology, Beijing 100071, China.

Jiansheng Lu (J)

Beijing Institute of Biotechnology, Beijing 100071, China.

Xuyang Liu (X)

Beijing Institute of Biotechnology, Beijing 100071, China.
Pharmaceutical College, Henan University, Kaifeng 475001, China.

Xiao Tan (X)

Beijing Institute of Biotechnology, Beijing 100071, China.
Institute of Life Science and Biotechnology, Beijing Jiaotong University, Beijing 100044, China.

Rong Wang (R)

Beijing Institute of Biotechnology, Beijing 100071, China.

Peng Du (P)

Beijing Institute of Biotechnology, Beijing 100071, China.

Shuo Yu (S)

Beijing Institute of Biotechnology, Beijing 100071, China.

Qing Xu (Q)

Institute of Life Science and Biotechnology, Beijing Jiaotong University, Beijing 100044, China.

Xiaobin Pang (X)

Pharmaceutical College, Henan University, Kaifeng 475001, China.

Yunzhou Yu (Y)

Beijing Institute of Biotechnology, Beijing 100071, China.

Zhixin Yang (Z)

Beijing Institute of Biotechnology, Beijing 100071, China.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH